IPSEN (IPN.PA) Stock Price & Overview
EPA:IPN • FR0010259150
The current stock price of IPN.PA is 154.2 EUR. Today IPN.PA is down by -4.16%. In the past month the price increased by 11.82%. In the past year, price increased by 40.82%.
IPN.PA Key Statistics
- Market Cap
- 12.924B
- P/E
- 15.01
- Fwd P/E
- 12.64
- EPS (TTM)
- 10.27
- Dividend Yield
- 0.85%
IPN.PA Stock Performance
IPN.PA Stock Chart
IPN.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IPN.PA. When comparing the yearly performance of all stocks, IPN.PA is one of the better performing stocks in the market, outperforming 92.25% of all stocks.
IPN.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to IPN.PA. IPN.PA has an excellent financial health rating, but there are some minor concerns on its profitability.
IPN.PA Earnings
On February 12, 2026 IPN.PA reported an EPS of 6.02 and a revenue of 1.86B. The company beat EPS expectations (9.26% surprise) and missed revenue expectations (-2.67% surprise).
IPN.PA Forecast & Estimates
19 analysts have analysed IPN.PA and the average price target is 142.63 EUR. This implies a price decrease of -7.5% is expected in the next year compared to the current price of 154.2.
For the next year, analysts expect an EPS growth of 10.9% and a revenue growth 8.75% for IPN.PA
IPN.PA Groups
Sector & Classification
IPN.PA Financial Highlights
Over the last trailing twelve months IPN.PA reported a non-GAAP Earnings per Share(EPS) of 10.27. The EPS increased by 12.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.25% | ||
| ROA | 11.21% | ||
| ROE | 17.93% | ||
| Debt/Equity | 0.19 |
IPN.PA Ownership
IPN.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 8.94 | 184.528B | ||
| SAN | SANOFI | 8.94 | 184.503B | ||
| 1SAN | SANOFI | 8.96 | 183.392B | ||
| UCB | UCB SA | 24.93 | 49.872B | ||
| UNC | UCB SA | 24.23 | 48.764B | ||
| 1MRK | MERCK KGAA | 12.53 | 46.826B | ||
| MRK | MERCK KGAA | 13.02 | 46.804B | ||
| BAYN | BAYER AG-REG | 8.03 | 36.929B | ||
| 1BAYN | BAYER AG-REG | 8.03 | 36.728B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.39 | 9.825B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.703B | ||
| VIRP | VIRBAC SA | 15.97 | 2.886B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About IPN.PA
Company Profile
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Company Info
IPO: 2005-12-06
IPSEN
65 Quai Georges Gorse
Boulogne-Billancourt ILE-DE-FRANCE FR
Employees: 5358
Phone: 33158335000
IPSEN / IPN.PA FAQ
What does IPN do?
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. The company is headquartered in Boulogne-Billancourt, Ile-De-France. The company went IPO on 2005-12-06. The firm operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
What is the stock price of IPSEN today?
The current stock price of IPN.PA is 154.2 EUR. The price decreased by -4.16% in the last trading session.
What is the dividend status of IPSEN?
IPSEN (IPN.PA) has a dividend yield of 0.85%. The yearly dividend amount is currently 1.2.
How is the ChartMill rating for IPSEN?
IPN.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What sector and industry does IPSEN belong to?
IPSEN (IPN.PA) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does IPSEN have?
IPSEN (IPN.PA) currently has 5358 employees.
What is the market capitalization of IPN stock?
IPSEN (IPN.PA) has a market capitalization of 12.92B EUR. This makes IPN.PA a Large Cap stock.